# Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

> **NCT04555304** · PHASE2 · UNKNOWN · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 81 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Cancer

## Interventions

- **DRUG:** KH903 + Paclitaxel
- **DRUG:** Placebo + Paclitaxel

## Key facts

- **NCT ID:** NCT04555304
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-15
- **Primary completion:** 2022-01-15
- **Final completion:** 2022-01-15
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2020-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04555304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04555304, "Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04555304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*